EP Global Communications Inc fka EPGL

[ElvisStock]

Q & A Session in Full Context

Welcome to tonight's EPGL Investor Q&A. We will go until 6:30 EST tonight. Ask your questions at [e-mail] if you have not yet.

Eric asks about the DTC issue. Eric, we have been told that the restrictions will be lifted this week. Stay tuned. We are relying on DTC to do this in a timely manner as all documents have been filed according to their requests. When a company has been non-reporting for over 2 years, in addition to the toxic financing it was under, the DTC made the restrictions. We are now clearing all that up. This will be a significant improvement in EPGL's liquidity, meaning that all brokers will allow purchasing of EPGL stock, when that has not been the case. EPGL management believes this issue could increase volume by on average 50% above current levels. We have had numerous people contact us, wanting to buy EPGL shares, but cannot. So, the takeaway is, stay tuned. It will happen very soon.

Charlie asks about OTCQX timing. Charlie, management is confident that EPGL will reach 10 cents in coming weeks, soon enough that the required time frames by OTC will be met. Managment believes that coming events and news will justify much higher share prices.. or should justify higher share prices. We cannot fully predict market conditions and unknown factors, but with new revenues on the way, new device progress and new benchmarks being reached, we are confident we will move up OTC tiers. Shareholders will benefit greatly if our plans are fully executed. We plan to fully execute our plans.

Roger asks about Pricewaterhouse shares. Roger, PWC is holding their shares firmly presently. They have not offered to sell them and we have not attempted to purchase them as yet. EPGL does have first right of refusal however.

Brent asks about MPDD manufacturing. Brent, we can say that devices will be existing to fill orders. Yes, we have orders to fill and many physicians are awaiting the availability of the devices. The feedback we are receiving on the MPDD in the field is absolutely solid and completely backs the original research done at NYU. This device offers all physicians a tool they do not presently have. Doctors practice "defensive medicine" today due to insurance and liability risks. One of the reasons EPGL is so enthusiastic about MPDD, is that is has the potential to become a required device by most insurance companies, Medicare and Medicaid. Because the device can save costs and more accurately diagnose what kind of condition the patient has physicians of all kinds will feel the need to have performed an evaluation with MPDD to avoid patient liability and to satisfy insurance requirements. EPGL managment believes that is the direction MPDD is headed and for that matter, all of the new devices slated in R&D.

Stephen asks about name change and ticker. Stephen, no we will never change the ticker symbol. It will remain EPGL and the name will change at some point this year. Please stay tuned on this front.

Binayak, PWC is a great partner in the restructuring and a major shareholder in EPGL. They are committed to significant growth of EPGL and the market capitalization before they will consider selling their holdings. Neither, they, nor Mr. Hayes will consider selling shares on a retail level such as was the case with NIR funds. The Company management has stated on several occasions now, that they are committed to shareholder equity growth and will not consider any transactions now or in the future that would be detrimental to EPGL shareholders. PWC and Hayes' interests are fully aligned with those of other holders of common shares.

Jeremy asks about moving up the release date. Jeremy, the release date was moved up because management felt it was imperative to do so, based on the demand the Company is beginning to see increase for the device and the follow up MPTT. In addition, management has received several heartfelt letters and emails from people suffering from back pain, migraines, neck pain and other forms of pain, which have them literally debilitated. Since the device is doing well in the initial doctors hands, that was the signal for us that justified moving up the release date. That plus some other upcoming events which will be made public in coming weeks, which affect the sales potential greatly for the MPDD and all EPGL devices forthcoming.

Anthony asks about other devices releases in 2013. Anthony, yes. The MPTT will be released by end of year if all goes to plan. Possibly two other devices. We refer you to our last Shareholder update PR which listed some of the devices under development. Anthony, As we are still at the beginning stages here, we will have announcements of Board of Director members and other executives coming..Stay tuned on that front. Shareholders should be encouraged to know that presently EPGL possesses technology which no other Medical Device companies presently have..Unique know-how and design of Biomems oriented devices is the key to EPGL success going forward.

We would like to thank all EPGL shareholders for being part of the newly restructured company. The uniqueness of EPGL is that it has many shareholders who originally invested in the Company long ago for very good reasons. The new EPGL will continue to do good work which will be beneficial to societies around the globe. This strong base of long-term shareholders, makes EPGL very unique.

Thank you for participating in tonight's QA session. EPGL Team will keep you updated on developments as they come and please watch for further updates and events in March, including the MPDD release, a Shareholder update on March 29 and our second Live Conference call to be held March 29, 2013 at 6:00PM EST. Also, stay tuned to Twitter daily as the Company will have regular updates here too.